MariMed Inc (MRMD)
OTHER OTC:MRMD
Want to see MRMD full AI Analyst Report?
MRMD Stock Chart & Stats
$0.07
<$0.01(0.85%)
At close: 4:00 PM EST
$0.07
<$0.01(0.85%)
Day’s Range― - ―
52-Week Range$0.06 - $0.23
Previous CloseN/A
Volume101.75K
Average Volume (3M)1.40M
Market Cap
$31.43M
Enterprise Value$125.50M
Total Cash (Recent Filing)$8.88M
Total Debt (Recent Filing)$100.09M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
May 13, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding397,882,750
10 Day Avg. Volume1,629,378
30 Day Avg. Volume1,398,937
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)0.66
Price to Sales (P/S)0.21
P/FCF Ratio5.25
Enterprise Value/Market Cap3.99
Enterprise Value/Revenue0.78
Enterprise Value/Gross Profit2.16
Enterprise Value/Ebitda13.29
Forecast
1Y Price Target
$0.25Price Target Upside257.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$164.30M
Bulls Say, Bears Say
Bulls Say
Multi‑year Revenue Growth And Wholesale ExpansionSustained revenue growth to ~$160M and accelerating wholesale (now 44% of sales, +11% YoY) indicate a scalable, diversified revenue base. Wholesale scale and multi‑state distribution reduce reliance on any single retail footprint, supporting durable topline resilience over the next 2–6 months.
Strong Brand Penetration And Category LeadershipHigh shelf penetration (~85%) and top category positions (e.g., Betty’s Eddies #1) reflect meaningful brand equity and distribution reach. These durable advantages support steady demand, easier new product rollouts, and bargaining power with retailers across core states over a multi‑quarter horizon.
Improving Cash Generation And Positive Adjusted EBITDA StreakConsistent positive operating cash flow and a return to positive free cash flow in 2025, alongside six consecutive years of positive adjusted EBITDA, point to improving internal cash generation. This enhances funding flexibility for operations and selective growth without sole dependence on external financing.
Bears Say
Material Margin Compression And Renewed Operating LossesSteady gross margin erosion and a shift back to operating losses indicate structural pricing pressure and worsening unit economics in mature markets. Without margin recovery, profitability and free cash conversion risk deteriorating, constraining sustainable earnings power over coming quarters.
Severely Strained Capital Structure And Equity ErosionA sharp leverage increase and collapsing equity reduce financial flexibility and heighten solvency risk. High leverage limits ability to fund investment organically, raises default and covenant risks, and increases the probability of dilutive financing if cash needs persist over the next several quarters.
Limited Cash Cushion And Higher Ongoing Interest BurdenModest cash balances combined with an elevated, recurring interest expense and replacement of a near‑term cash obligation with longer‑dated notes and senior preferred create a tighter liquidity profile. This limits runway for investments and raises sensitivity to industry volatility over the medium term.
MariMed News
MRMD FAQ
What was MariMed Inc’s price range in the past 12 months?
MariMed Inc lowest stock price was $0.06 and its highest was $0.23 in the past 12 months.
What is MariMed Inc’s market cap?
MariMed Inc’s market cap is $31.43M.
When is MariMed Inc’s upcoming earnings report date?
MariMed Inc’s upcoming earnings report date is May 13, 2026 which is in 15 days.
How were MariMed Inc’s earnings last quarter?
MariMed Inc released its earnings results on Mar 11, 2026. The company reported $0.006 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.016.
Is MariMed Inc overvalued?
According to Wall Street analysts MariMed Inc’s price is currently Undervalued.
Does MariMed Inc pay dividends?
MariMed Inc does not currently pay dividends.
What is MariMed Inc’s EPS estimate?
MariMed Inc’s EPS estimate is -0.01.
How many shares outstanding does MariMed Inc have?
MariMed Inc has 397,882,750 shares outstanding.
What happened to MariMed Inc’s price movement after its last earnings report?
MariMed Inc reported an EPS of $0.006 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went down -2.532%.
Which hedge fund is a major shareholder of MariMed Inc?
Currently, no hedge funds are holding shares in MRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MariMed Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.58%
12-Months-Change
Fundamentals
Return on Equity
-24.95%
Trailing 12-Months
Asset Growth
-2.14%
Trailing 12-Months
Company Description
MariMed Inc
MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company offers cannabis genetics produce flowers and concentrates under the Nature's Heritage brand; cannabis-infused products in the form of chewable tablets and powder drink mixes under the brand Kalm Fusion; natural fruit chews under the Betty's Eddies brand; brownies, cookies, and other social sweets under the Bubby's Baked brand; and cannabidiol formulations under the Florance brand. It also licenses its brands and product formulations, as well as leases cannabis facilities. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.
MRMD Company Deck
MRMD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a cautiously optimistic tone: MariMed reported continued brand and wholesale momentum (category leadership, expanded penetration, wholesale growth, Delaware AU traction), maintained positive adjusted EBITDA streak, and executed balance sheet actions to improve flexibility. However, the company is facing notable margin and retail headwinds in mature markets (notably Illinois and Massachusetts), experienced declines in EBITDA and operating income YoY, and has limited near‑term cash reserves. Management emphasized disciplined cost control, asset‑light licensing expansion, and selective M&A, while acknowledging timing risk for new market contributions.View all MRMD earnings summariesMRMD Stock 12 Month Forecast
Average Price Target
$0.25
▲(257.14% Upside)
Technical Analysis
Ownership Overview
10.70% Insiders
0.18% Other Institutional Investors
89.12% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---